Viral Hepatitis Prevention Board (VHPB) - Meeting Programme -
Malta, October 22-23, 2001
Combined hepatitis B vaccines Monday, October 22, 2001
Session 1 Opening and objectivesChair: Peter Grob and André Meheus 09.00-09.15
- Introduction of the participants.
- Objectives of the meeting:
- Take stock of the currently available/licensed combined hepatitis B vaccines in the European countries;
- Review the data on the hexavalent HB-Hib-DTPa-IPV vaccines: safety, immunogenicity, license, and availability in Europe;
- Update the information on future combined hepatitis B vaccines;
- Review the infant immunisation schedules in Europe;
- Discuss the impact of the availability of combined hepatitis B vaccines on the hepatitis B immunisation programmes in Europe;
- Discuss the added value of combined hepatitis B vaccines in a global perspective.
- Review of the meeting programme.
- Combined hepatitis B vaccines: an overview of the situation - Pre-meeting document. 93 Kb (.doc)
Session 2 Vaccination schedules and programmesChair: Peter Grob and André Meheus 9.15-9.30
Overview of the vaccination programme in Malta. 125 Kb (.ppt)
Mark Muscat (Public Health Department, Malta)
Countries in Europe where combined vaccines are licensed. 27 Kb (.ppt)
Pierre Van Damme (VHPB)
Infant and adolescent vaccination schedules in Europe - anno 2001. 86 Kb (.ppt)
Nicole Guérin (Comité Technique Vaccinations, France)
Infant and adolescent hepatitis B vaccination and use of combination vaccines - USA. 229 Kb (.ppt)
Fred Shaw (CDC, USA)
Feedback from the respective countries: The use of combined vaccines in universal vaccination programmes, for individuals or selected groups, … - Recent or future changes in vaccination schedules due to the availability of combined vaccines.
Harmonisation of vaccination calendars in the European countries: pros and cons.
Michael Pfleiderer (Paul-Ehrlich-Instititut, Germany)
Session 3 Current and new combined vaccinesChair: Johannes Hallauer and Colette Roure
European regulatory authorities' perspective and view on proving safety and immunogenicity of combined vaccines - General aspects - Recent experiences. 61 Kb (.ppt)
Michael Pfleiderer (Paul-Ehrlich-Institute, Germany)
Combined vaccines with a hepatitis B component - The role of non-clinical testing in ensuring their safety and efficacy. 360 Kb (.ppt)
Roland Dobbelaer (Scientific Institute of Public Health, Belgium)
New vaccine supply and financing: a case study of combination vaccines in developing countries. 417 Kb (.ppt)
Susan McKinney (WHO, Switzerland)
Influence of combined vaccines on infant immunisation coverage – Recent data from Italy [Factors influencing vaccine uptake in Italy], Germany [Germany: recommendations and delivery of vaccines], and Belgium [Analysis of factors influencing vaccine uptake: perspectives from Belgium]. 1,098 Kb (.ppt)
Paolo Bonanni (University of Florence, Italy)
Round table discussion: a global perspective on combined vaccines.
Combined vaccines now and in the future; What do we need from a public health point of view? Pros and cons for industrialised countries and developing countries? What is being developed: a perspective from the industry?
Moderators: André Meheus(University of Antwerpen, Belgium) and Andrei Lobanov (WHO, Denmark)
Special Session Chair: Paolo Bonanni and Peter Grob:
Feedback on 'Peter Grob et al. Laboratory surveillance, screening, and diagnostics of HBV infection. 2001', in preparation.
Close of the day by the chair - Housekeeping announcements.
Tuesday, October 23, 2001
Session 4 Combined vaccines: where is the limit?Chair: Wolfgang Jilg and Daniel Shouval 9.00-9.40
Hepatitis B vaccination: an alternative (re)view. 984 Kb (.ppt)
Geert Leroux-Roels (Ghent University, Belgium)
Importance of combined hepatitis B vaccines - Point of view of a paediatrician. 187 Kb (.ppt)
Vytautas Usonis (Vilnius University Centre of Paediatrics, Lithuania)
Immunogenicity profile of combined vaccines in infants. 508 Kb (.ppt)
Helena Käyhty (National Public Health Institute, Finland)
Combined paediatric vaccines for national immunisation programmes. 1,631 Kb (.ppt)
Francis André (GlaxoSmithKline, Belgium)
HEXAVACÒ - A new liquid DTacP-IPV-Hib-HB hexavalent vaccine - Overview of its clinical profile. 286 Kb(.ppt)
Benoît Soubeyrand (Aventis Pasteur, France)
Discussion, including: Safety issues in the production of combined versus monovalent vaccines - Stocks of combined vaccines - How to encourage companies to produce combined vaccines? - …
Session 5 Impact of introducing combined vaccines Chair: Nicole Guérin and Andrei Lobanov 14.00-14.20
Economic aspects of combined vaccines. 59 Kb (.ppt)
Philippe Beutels (University of Antwerpen, Belgium)
Decision-making process and impact of implementation of hexavalent vaccines in national immunisation programmes: the case of Germany. 62 Kb (.ppt)
Wolfgang Jilg (University of Regensburg, Germany) Discussion, including: Why countries do or do not introduce combined vaccines - Impact of vaccines on the decision-making process.
Session 6 Conclusions of the meetingChair: Pierre Van Damme
Presentation of the VHPB conclusions. 46 Kb (.ppt)
David FitzSimons (WHO, Switzerland)
Closing of the meeting.